OncoCyte (NYSE: OCX) is one of 31 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its competitors? We will compare OncoCyte to related businesses based on the strength of its risk, institutional ownership, profitability, dividends, analyst recommendations, valuation and earnings.
Risk and Volatility
OncoCyte has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, OncoCyte’s competitors have a beta of 1.61, meaning that their average stock price is 61% more volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for OncoCyte and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
OncoCyte currently has a consensus target price of $2.00, indicating a potential upside of 27.39%. As a group, “Diagnostic substances” companies have a potential downside of 6.97%. Given OncoCyte’s stronger consensus rating and higher possible upside, analysts plainly believe OncoCyte is more favorable than its competitors.
Earnings & Valuation
This table compares OncoCyte and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|OncoCyte Competitors||$332.02 million||-$15.49 million||104.14|
OncoCyte’s competitors have higher revenue and earnings than OncoCyte. OncoCyte is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares OncoCyte and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
49.2% of OncoCyte shares are held by institutional investors. Comparatively, 53.0% of shares of all “Diagnostic substances” companies are held by institutional investors. 5.6% of OncoCyte shares are held by company insiders. Comparatively, 8.4% of shares of all “Diagnostic substances” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
OncoCyte competitors beat OncoCyte on 7 of the 13 factors compared.
OncoCyte Corporation engages in the development and commercialization of non-invasive blood-based diagnostic tests for the early detection of cancer. The company is developing DetermaVu, a non-invasive molecular lung cancer confirmatory diagnostic that is administered to patients as a blood test. It also develops diagnostic tests based on liquid biopsies for detecting breast cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.